Educational Objectives
The PHA Preceptorship Program is designed to instruct front-line clinicians in the highest quality of care for patients with PAH. At the conclusion of this program, participants should be able to:
- Define key pathophysiologic and epidemiologic components of PAH
- Accurately diagnose patients through comprehensive screening and early recognition of symptoms
- Evaluate the patient’s condition and prescribe optimal long-term management, including knowing when and how to treat and when to consult with colleagues at an established PAH center
- Tailor comprehensive care for complex patient populations
The combination of didactic discourse and highly interactive case-based discussions will provide those attending with:
- Concise, clinically relevant information
- New or refined skills that will improve patient care
- Up-to-date referral resources and strengthened relationships with the nearest established PAH center
- Better awareness of and access to clinical trials that might be of benefit to their patients.
AMA Category 1 credit will be available for this activity.
DIAMOND SUPPORTER
|
PLATINUM SUPPORTER
|
GOLD SUPPORTER
|
SILVER SUPPORTER
|
| Actelion Pharmaceuticals US, Inc. |
Gilead Sciences, Inc. |
United Therapeutics Corporation |
Bayer HealthCare |
This is a program of the PHA Medical Education Fund, made possible through unrestricted educational grants from our supporters.